Using 18F-PSMA PET/CT imaging for detecting prostate-specific tumors
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
This study is testing a new type of imaging to see if it can better find prostate-specific tumors in patients with prostate cancer and other related cancers.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing, Chaoyang) |
| Trial ID | NCT05761366 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Al18F-PSMA-BCH PET/CT imaging in detecting tumors that express prostate-specific membrane antigen (PSMA). It includes patients with various types of malignancies known to express PSMA, such as prostate cancer and several other carcinomas. The study aims to assess how well this imaging technique can identify these tumors, potentially improving diagnosis and treatment planning.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with suspected or diagnosed PSMA positive-expressing tumors.
Not a fit: Patients with serious underlying health conditions or those who have recently participated in other experimental treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could enhance the accuracy of tumor detection in patients with PSMA positive tumors, leading to better treatment outcomes.
How similar studies have performed: Other studies have shown promise in using PSMA-targeted imaging for tumor detection, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc. 2. Age is 18 or older; No gender limitation. 3. Signed the informed consent. 4. Willing and able to cooperate with all projects in this study. Exclusion Criteria: 1. Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc 2. Claustrophobia. 3. Pregnant or lactation women. 4. Received experimental drug or device within 1 month.
Where this trial is running
Beijing, Chaoyang
- National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Chaoyang, China (Recruiting)
Study contacts
- Principal investigator: Rong Zheng, MD — National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and PUMC
- Study coordinator: Xin Cheng, MD
- Email: cxpumc@foxmail.com
- Phone: 15120002998
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.